Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Evoked potentials as a translatable biomarker to track functional remyelination.

Farley BJ, Morozova E, Dion J, Wang B, Harvey BD, Gianni D, Wipke B, Cadavid D, Wittmann M, Hajos M.

Mol Cell Neurosci. 2019 Jul 26;99:103393. doi: 10.1016/j.mcn.2019.103393. [Epub ahead of print]

PMID:
31356882
2.

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.

Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulović J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Cheng W, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh SI; SYNERGY study investigators.

Lancet Neurol. 2019 Sep;18(9):845-856. doi: 10.1016/S1474-4422(19)30137-1. Epub 2019 Jul 5.

PMID:
31285147
3.

Ligand-Mediated Band Engineering in Bottom-Up Assembled SnTe Nanocomposites for Thermoelectric Energy Conversion.

Ibáñez M, Hasler R, Genç A, Liu Y, Kuster B, Schuster M, Dobrozhan O, Cadavid D, Arbiol J, Cabot A, Kovalenko MV.

J Am Chem Soc. 2019 May 22;141(20):8025-8029. doi: 10.1021/jacs.9b01394. Epub 2019 Apr 24.

4.

Crystallographically textured SnSe nanomaterials produced from the liquid phase sintering of nanocrystals.

Li M, Liu Y, Zhang Y, Zuo Y, Li J, Lim KH, Cadavid D, Ng KM, Cabot A.

Dalton Trans. 2019 Mar 12;48(11):3641-3647. doi: 10.1039/c8dt04414g.

PMID:
30758366
5.

Voice of People with Fragile X Syndrome and Their Families: Reports from a Survey on Treatment Priorities.

Weber JD, Smith E, Berry-Kravis E, Cadavid D, Hessl D, Erickson C.

Brain Sci. 2019 Jan 23;9(2). pii: E18. doi: 10.3390/brainsci9020018.

6.

Large-area and adaptable electrospun silicon-based thermoelectric nanomaterials with high energy conversion efficiencies.

Morata A, Pacios M, Gadea G, Flox C, Cadavid D, Cabot A, Tarancón A.

Nat Commun. 2018 Nov 12;9(1):4759. doi: 10.1038/s41467-018-07208-8.

7.

Tin Diselenide Molecular Precursor for Solution-Processable Thermoelectric Materials.

Zhang Y, Liu Y, Lim KH, Xing C, Li M, Zhang T, Tang P, Arbiol J, Llorca J, Ng KM, Ibáñez M, Guardia P, Prato M, Cadavid D, Cabot A.

Angew Chem Int Ed Engl. 2018 Dec 21;57(52):17063-17068. doi: 10.1002/anie.201809847. Epub 2018 Nov 25.

PMID:
30398301
8.

Predictors of response to opicinumab in acute optic neuritis.

Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch LJ, Leocani L, Freedman MS, Plant GT, Preiningerova JL, Ziemssen F, Massacesi L, Chai Y, Xu L; RENEW Study Investigators.

Ann Clin Transl Neurol. 2018 Aug 15;5(10):1154-1162. doi: 10.1002/acn3.620. eCollection 2018 Oct.

9.

Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential.

Klistorner A, Chai Y, Leocani L, Albrecht P, Aktas O, Butzkueven H, Ziemssen T, Ziemssen F, Frederiksen J, Xu L, Cadavid D; RENEW MF-VEP Investigators.

CNS Drugs. 2018 Dec;32(12):1159-1171. doi: 10.1007/s40263-018-0575-8.

10.

Initial Impairment and Recovery of Vision-Related Functioning in Participants With Acute Optic Neuritis From the RENEW Trial of Opicinumab.

Petrillo J, Balcer L, Galetta S, Chai Y, Xu L, Cadavid D.

J Neuroophthalmol. 2019 Jun;39(2):153-160. doi: 10.1097/WNO.0000000000000697.

11.

Development of a gait module to complement the 12-item Multiple Sclerosis Walking Scale: a mixed methods study.

Strzok S, Cleanthous S, Pompilus F, Cano SJ, Marquis P, Cohan S, Goldman MD, Kresa-Reahl K, Petrillo J, Castrillo-Viguera C, Cadavid D, Chen SY.

Mult Scler J Exp Transl Clin. 2018 Jun 26;4(2):2055217318783766. doi: 10.1177/2055217318783766. eCollection 2018 Apr-Jun.

12.

High Thermoelectric Performance in Crystallographically Textured n-Type Bi2Te3- xSe x Produced from Asymmetric Colloidal Nanocrystals.

Liu Y, Zhang Y, Lim KH, Ibáñez M, Ortega S, Li M, David J, Martí-Sánchez S, Ng KM, Arbiol J, Kovalenko MV, Cadavid D, Cabot A.

ACS Nano. 2018 Jul 24;12(7):7174-7184. doi: 10.1021/acsnano.8b03099. Epub 2018 Jul 9.

PMID:
29966413
13.

Addressing the targeting range of the ABILHAND-56 in relapsing-remitting multiple sclerosis: A mixed methods psychometric study.

Cleanthous S, Strzok S, Pompilus F, Cano S, Marquis P, Cohan S, Goldman MD, Kresa-Reahl K, Petrillo J, Castrillo-Viguera C, Cadavid D, Chen SY.

Mult Scler J Exp Transl Clin. 2018 May 17;4(2):2055217318776990. doi: 10.1177/2055217318776990. eCollection 2018 Apr-Jun.

14.

Crystallographically Textured Nanomaterials Produced from the Liquid Phase Sintering of Bi xSb2- xTe3 Nanocrystal Building Blocks.

Liu Y, Zhang Y, Ortega S, Ibáñez M, Lim KH, Grau-Carbonell A, Martí-Sánchez S, Ng KM, Arbiol J, Kovalenko MV, Cadavid D, Cabot A.

Nano Lett. 2018 Apr 11;18(4):2557-2563. doi: 10.1021/acs.nanolett.8b00263. Epub 2018 Mar 20.

PMID:
29546994
15.

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.

Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators.

Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12.

PMID:
29545067
16.

Tuning p-Type Transport in Bottom-Up-Engineered Nanocrystalline Pb Chalcogenides Using Alkali Metal Chalcogenides as Capping Ligands.

Ibáñez M, Hasler R, Liu Y, Dobrozhan O, Nazarenko O, Cadavid D, Cabot A, Kovalenko MV.

Chem Mater. 2017 Sep 12;29(17):7093-7097. doi: 10.1021/acs.chemmater.7b02967. Epub 2017 Aug 23. No abstract available.

17.

Optimal Intereye Difference Thresholds in Retinal Nerve Fiber Layer Thickness for Predicting a Unilateral Optic Nerve Lesion in Multiple Sclerosis.

Nolan RC, Galetta SL, Frohman TC, Frohman EM, Calabresi PA, Castrillo-Viguera C, Cadavid D, Balcer LJ.

J Neuroophthalmol. 2018 Dec;38(4):451-458. doi: 10.1097/WNO.0000000000000629.

PMID:
29384802
18.

Anti-LINGO-1 has no detectable immunomodulatory effects in preclinical and phase 1 studies.

Ranger A, Ray S, Szak S, Dearth A, Allaire N, Murray R, Gardner R, Cadavid D, Mi S.

Neurol Neuroimmunol Neuroinflamm. 2017 Dec 15;5(1):e417. doi: 10.1212/NXI.0000000000000417. eCollection 2018 Jan.

19.

Survival of Endodontically Treated Roots/Teeth Based on Periapical Health and Retention: A 10-year Retrospective Cohort Study.

Fernández R, Cardona JA, Cadavid D, Álvarez LG, Restrepo FA.

J Endod. 2017 Dec;43(12):2001-2008. doi: 10.1016/j.joen.2017.08.003. Epub 2017 Oct 20.

PMID:
29061351
20.

MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis.

Maranzano J, Rudko DA, Nakamura K, Cook S, Cadavid D, Wolansky L, Arnold DL, Narayanan S.

Neurology. 2017 Aug 15;89(7):714-721. doi: 10.1212/WNL.0000000000004227. Epub 2017 Jul 19.

21.

Bottom-up engineering of thermoelectric nanomaterials and devices from solution-processed nanoparticle building blocks.

Ortega S, Ibáñez M, Liu Y, Zhang Y, Kovalenko MV, Cadavid D, Cabot A.

Chem Soc Rev. 2017 Jun 19;46(12):3510-3528. doi: 10.1039/c6cs00567e.

PMID:
28470243
22.

Oxidation at the atomic scale.

Cadavid D, Cabot A.

Science. 2017 Apr 21;356(6335):245. doi: 10.1126/science.aan0979. Epub 2017 Apr 20. No abstract available.

PMID:
28428381
23.

Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial.

Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch L, Frederiksen J, Skeen M, Jaffe GJ, Butzkueven H, Ziemssen F, Massacesi L, Chai Y, Xu L, Freeman S; RENEW Study Investigators.

Lancet Neurol. 2017 Mar;16(3):189-199. doi: 10.1016/S1474-4422(16)30377-5. Epub 2017 Feb 15.

PMID:
28229892
24.

Antibiotics for the neurological complications of Lyme disease.

Cadavid D, Auwaerter PG, Rumbaugh J, Gelderblom H.

Cochrane Database Syst Rev. 2016 Dec 8;12:CD006978. doi: 10.1002/14651858.CD006978.pub2. Review.

25.

Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale.

Goldman MD, Ward MD, Motl RW, Jones DE, Pula JH, Cadavid D.

Mult Scler. 2017 Sep;23(10):1405-1414. doi: 10.1177/1352458516680749. Epub 2016 Dec 7.

26.

MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b.

Brown RA, Narayanan S, Stikov N, Cook S, Cadavid D, Wolansky L, Arnold DL.

Neurology. 2016 Aug 30;87(9):905-11. doi: 10.1212/WNL.0000000000003043. Epub 2016 Jul 29.

27.

Mn3O4@CoMn2O4-CoxOy Nanoparticles: Partial Cation Exchange Synthesis and Electrocatalytic Properties toward the Oxygen Reduction and Evolution Reactions.

Luo Z, Irtem E, Ibáñez M, Nafria R, Martı́-Sánchez S, Genç A, de la Mata M, Liu Y, Cadavid D, Llorca J, Arbiol J, Andreu T, Morante JR, Cabot A.

ACS Appl Mater Interfaces. 2016 Jul 13;8(27):17435-44. doi: 10.1021/acsami.6b02786. Epub 2016 Jun 30.

PMID:
27323284
28.

The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.

Cadavid D, Cohen JA, Freedman MS, Goldman MD, Hartung HP, Havrdova E, Jeffery D, Kapoor R, Miller A, Sellebjerg F, Kinch D, Lee S, Shang S, Mikol D.

Mult Scler. 2017 Jan;23(1):94-105. doi: 10.1177/1352458516638941. Epub 2016 Jul 11.

PMID:
27003945
29.

High-performance thermoelectric nanocomposites from nanocrystal building blocks.

Ibáñez M, Luo Z, Genç A, Piveteau L, Ortega S, Cadavid D, Dobrozhan O, Liu Y, Nachtegaal M, Zebarjadi M, Arbiol J, Kovalenko MV, Cabot A.

Nat Commun. 2016 Mar 7;7:10766. doi: 10.1038/ncomms10766.

30.

Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis.

Sellebjerg F, Cadavid D, Steiner D, Villar LM, Reynolds R, Mikol D.

Ther Adv Neurol Disord. 2016 Jan;9(1):31-43. doi: 10.1177/1756285615615257. Review.

31.

Correction to "Electron Doping in Bottom-Up Engineered Thermoelectric Nanomaterials through HCl-Mediated Ligand Displacement".

Ibáñez M, Korkosz R, Luo Z, Riba P, Cadavid D, Ortega S, Cabot A, Kanatzidis MG.

J Am Chem Soc. 2015 Sep 16;137(36):11854. doi: 10.1021/jacs.5b08296. Epub 2015 Sep 2. No abstract available.

PMID:
26332181
32.

Acute optic neuritis: Unmet clinical needs and model for new therapies.

Galetta SL, Villoslada P, Levin N, Shindler K, Ishikawa H, Parr E, Cadavid D, Balcer LJ.

Neurol Neuroimmunol Neuroinflamm. 2015 Jul 23;2(4):e135. doi: 10.1212/NXI.0000000000000135. eCollection 2015 Aug. Review.

33.

Assessing clinical correlates of self-rated disability in patients with multiple sclerosis.

Magistrale G, Medori R, Cadavid D, Argento O, Incerti C, Pisani V, Caltagirone C, Bozzali M, DeLuca J, Nocentini U.

Mult Scler J Exp Transl Clin. 2015 Jul 8;1:2055217315592425. doi: 10.1177/2055217315592425. eCollection 2015 Jan-Dec.

34.

Longitudinal changes in self-reported walking ability in multiple sclerosis.

Motl RW, Putzki N, Pilutti LA, Cadavid D.

PLoS One. 2015 May 1;10(5):e0125002. doi: 10.1371/journal.pone.0125002. eCollection 2015.

35.

Hypophosphatemia is Associated with the Serial Administration of Triple-Dose Gadolinium to Patients for Brain MRI.

Wolansky LJ, Cadavid D, Punia V, Kim S, Cheriyan J, Haghighi M, Cook SD.

J Neuroimaging. 2015 May-Jun;25(3):379-83. doi: 10.1111/jon.12241. Epub 2015 Apr 13.

PMID:
25867798
36.

Electron doping in bottom-up engineered thermoelectric nanomaterials through HCl-mediated ligand displacement.

Ibáñez M, Korkosz RJ, Luo Z, Riba P, Cadavid D, Ortega S, Cabot A, Kanatzidis MG.

J Am Chem Soc. 2015 Apr 1;137(12):4046-9. doi: 10.1021/jacs.5b00091. Epub 2015 Mar 17. Erratum in: J Am Chem Soc. 2015 Sep 16;137(36):11854.

PMID:
25762361
37.

Polyomavirus-associated nephropathy in renal and simultaneous pancreas-kidney transplant recipients: report of three cases.

Cadavid D, Mesa L, Schweineberg J, Posada JG.

Saudi J Kidney Dis Transpl. 2015 Jan;26(1):94-7.

38.

Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033.

Tran JQ, Rana J, Barkhof F, Melamed I, Gevorkyan H, Wattjes MP, de Jong R, Brosofsky K, Ray S, Xu L, Zhao J, Parr E, Cadavid D.

Neurol Neuroimmunol Neuroinflamm. 2014 Aug 21;1(2):e18. doi: 10.1212/NXI.0000000000000018. eCollection 2014 Aug.

39.

Validation of the World Health Organization Disability Assessment Schedule II (WHODAS-II) in patients with multiple sclerosis.

Magistrale G, Pisani V, Argento O, Incerti CC, Bozzali M, Cadavid D, Caltagirone C, Medori R, DeLuca J, Nocentini U.

Mult Scler. 2015 Apr;21(4):448-56. doi: 10.1177/1352458514543732. Epub 2014 Aug 4.

PMID:
25092769
40.

Reliability of a cognitive endpoint for use in a multiple sclerosis pharmaceutical trial.

Erlanger DM, Kaushik T, Caruso LS, Benedict RH, Foley FW, Wilken J, Cadavid D, Deluca J.

J Neurol Sci. 2014 May 15;340(1-2):123-9. doi: 10.1016/j.jns.2014.03.009. Epub 2014 Mar 11.

41.

Antibodies to endothelial cell growth factor and obliterative microvascular lesions in the synovium of patients with antibiotic-refractory lyme arthritis.

Londoño D, Cadavid D, Drouin EE, Strle K, McHugh G, Aversa JM, Steere AC.

Arthritis Rheumatol. 2014 Aug;66(8):2124-33. doi: 10.1002/art.38618.

42.

Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis.

Edwards KR, Goyal J, Plavina T, Czerkowicz J, Goelz S, Ranger A, Cadavid D, Browning JL.

PLoS One. 2013 Nov 20;8(11):e81007. doi: 10.1371/journal.pone.0081007. eCollection 2013.

43.

The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.

Wattjes MP, Richert ND, Killestein J, de Vos M, Sanchez E, Snaebjornsson P, Cadavid D, Barkhof F.

Mult Scler. 2013 Dec;19(14):1826-40. doi: 10.1177/1352458513510224. Epub 2013 Nov 5. Review.

PMID:
24192217
44.

Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world.

Goldman MD, Motl RW, Scagnelli J, Pula JH, Sosnoff JJ, Cadavid D.

Neurology. 2013 Nov 19;81(21):1856-63. doi: 10.1212/01.wnl.0000436065.97642.d2. Epub 2013 Oct 30.

45.

Cognitive processing speed has minimal influence on the construct validity of Multiple Sclerosis Walking Scale-12 scores.

Motl RW, Cadavid D, Sandroff BM, Pilutti LA, Pula JH, Benedict RH.

J Neurol Sci. 2013 Dec 15;335(1-2):169-73. doi: 10.1016/j.jns.2013.09.024. Epub 2013 Sep 24.

PMID:
24104065
46.

Impact of three radiographic methods in the outcome of nonsurgical endodontic treatment: a five-year follow-up.

Fernández R, Cadavid D, Zapata SM, Alvarez LG, Restrepo FA.

J Endod. 2013 Sep;39(9):1097-103. doi: 10.1016/j.joen.2013.04.002. Epub 2013 May 21.

PMID:
23953279
47.

Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic.

Mi S, Pepinsky RB, Cadavid D.

CNS Drugs. 2013 Jul;27(7):493-503. doi: 10.1007/s40263-013-0068-8. Review.

PMID:
23681979
48.

CuTe nanocrystals: shape and size control, plasmonic properties, and use as SERS probes and photothermal agents.

Li W, Zamani R, Rivera Gil P, Pelaz B, Ibáñez M, Cadavid D, Shavel A, Alvarez-Puebla RA, Parak WJ, Arbiol J, Cabot A.

J Am Chem Soc. 2013 May 15;135(19):7098-101. doi: 10.1021/ja401428e. Epub 2013 May 6.

PMID:
23647089
49.

Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis.

Learmonth YC, Motl RW, Sandroff BM, Pula JH, Cadavid D.

BMC Neurol. 2013 Apr 25;13:37. doi: 10.1186/1471-2377-13-37.

50.

Metal ions to control the morphology of semiconductor nanoparticles: copper selenide nanocubes.

Li W, Zamani R, Ibáñez M, Cadavid D, Shavel A, Morante JR, Arbiol J, Cabot A.

J Am Chem Soc. 2013 Mar 27;135(12):4664-7. doi: 10.1021/ja400472m. Epub 2013 Mar 12.

PMID:
23470030

Supplemental Content

Loading ...
Support Center